Modulation of Janus kinase 2 by p53 in ovarian cancer cells

Biochemical and Biophysical Research Communications

Volumn 321, Issue 2, 2004, Pages 441-447

  Reid, Thomas ^a   Jin, Xiaohong ^a   Song, Hui ^a   Tang, Huai Jing ^a   Reynolds, R Kevin ^a   Lin, Jiayuh ^a  

^a Department of Obstetrics   (United States)

Author keywords

JAK2; Ovarian cancer; p53

Indexed keywords

ADENOVIRUS VECTOR; JANUS KINASE 2; MITOGEN ACTIVATED PROTEIN KINASE 1; MUTANT PROTEIN; PROTEIN KINASE; PROTEIN P53; PROTEIN TYROSINE PHOSPHATASE 1B; VANADATE SODIUM; DNA BINDING PROTEIN; JAK2 PROTEIN, HUMAN; JAK2 PROTEIN, MOUSE; ONCOPROTEIN; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE PHOSPHATASE; STAT3 PROTEIN; STAT3 PROTEIN, HUMAN; STAT3 PROTEIN, MOUSE; TRANSACTIVATOR PROTEIN; VANADIC ACID;

ARTICLE; CANCER CELL CULTURE; CONTROLLED STUDY; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; ENZYME REGULATION; FEMALE; GENE TRANSFER; HUMAN; HUMAN CELL CULTURE; HUMAN TISSUE; OVARY CANCER; PRIORITY JOURNAL; PROTEIN DEPHOSPHORYLATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; TUMOR SUPPRESSOR GENE; WILD TYPE; ANIMAL; APOPTOSIS; ENZYMOLOGY; FIBROBLAST; GENE DELETION; GENETICS; METABOLISM; MOUSE; OVARY TUMOR; PATHOLOGY; PHOSPHORYLATION; SIGNAL TRANSDUCTION; TUMOR CELL LINE;

ADENOVIRIDAE; JANUS;

ANIMALS; APOPTOSIS; CELL LINE, TUMOR; DNA-BINDING PROTEINS; FEMALE; FIBROBLASTS; GENE DELETION; HUMANS; JANUS KINASE 2; MAP KINASE SIGNALING SYSTEM; MICE; OVARIAN NEOPLASMS; PHOSPHORYLATION; PROTEIN-TYROSINE KINASES; PROTEIN-TYROSINE-PHOSPHATASE; PROTO-ONCOGENE PROTEINS; STAT3 TRANSCRIPTION FACTOR; TRANS-ACTIVATORS; TUMOR SUPPRESSOR PROTEIN P53; VANADATES;

EID: 3242805180     PISSN: 0006291X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bbrc.2004.06.169     Document Type: Article

References (33)

1. S. Kuerbitz, B. Plunkett, W. Walsh and M. Kastan Wild-type p53 is a cell cycle checkpoint determinant following irradiation Proc. Natl. Acad. Sci. USA 89 1992 7491 7495
2. S. Lowe, E. Schmitt, S. Smith, B. Osborne and T. Jacks p53 is required for radiation-induced apoptosis in mouse thymocytes Nature (Lond.) 362 1993 847 849
3. J.N. Ihle The Janus protein tyrosine kinase family and its role in cytokine signaling Adv. Immunol. 60 1995 1 35
4. M. Narazaki, B. Witthuhn, K. Yoshida, O. Silvennoinen, K. Yasukawa, J. Ihle, T. Kishinito and T. Taga Activation of JAK2 kinase mediated by the interleukin 6 signal transducer gp130 Proc. Natl. Acad. Sci. USA 91 1994 2285 2289
5. R. Garcia, T. Bowman, G. Niu, H. Yu, S. Minton, C. Muro-Cacho, C.E. Cox, R. Falcone, R. Fairclough, S. Parsons, A. Laudano, A. Gazit, A. Levitzki and A. Kraker Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells Oncogene 20 2002 2499 2513
6. T. Bowman, R. Garcia, J. Turkson and R. Jove Stats in oncogenesis Oncogene 19 2000 2474 2488
7. R. Garcia, C. Yu, A. Hudnall, R. Catlett, K. Nelson, T. Smithgall, D.J. Fujita, S.D. Ethier and R. Jove Constitutive activation of Stat 3 in fibroblasts transformed by diverse oncoproteins and in breast carcinoma cells Cell Growth Differ. 8 1997 1267 1275
8. H. Ruchatz, A. Coluccia, P. Stano, E. Marchesi and C. Gambacorti-Passerini Constitutive activation of Jak2 contributes to proliferation and resistance to apoptosis in NPM/ALK-transformed cells Exp. Hematol. 31 2003 309 315
9. V. Lacronique, A. Boureux, R. Monni, S. Dumon, M. Mauchauffe, P. Mayeux, F. Gouilleux, R. Berger, S. Gisselbretch, J. Ghysdael and O.A. Bernard Transforming properties of chimeric TEL-JAK proteins in Ba/F3 cells Blood 95 2000 2076 2083
10. C. Carron, F. Cormier, A. Janin, V. Lacronique, M. Giovannini, M.T. Daniel, O. Bernard and J. Ghysdael TEL-JAK2 transgenic mice develop T-cell leukemia Blood 95 2000 3891 3899
11. C. Liu, T. Itoh, K. Arai and S. Watanabe Constitutive activation of JAK2 confers murine interleukin-3-independent survival and proliferation of BA/F3 cells J. Biol. Chem. 274 1999 6342 6349
12. R. Liu, C. Fan, R. Garcia, R. Jove and K. Zuckerman Constitutive activation of the JAK2/Stat5 signal transduction pathway correlates with growth factor independence of megakaryocytic leukemic cell line Blood 93 1999 2369 2379
13. H. Yoshikawa, K. Matsubara, G. Qian, P. Jackson, J. Groopman, J. Manning, C.C. Harris and J.G. Herman SOCS-1, a negative regulator of the JAK/Stat pathway, is silenced by methylation in human hepatocellular carcinoma and shows growth-suppression activity Nat. Genet. 28 2001 29 35
14. J. Lin, H. Tang, X. Jin, G. Jia and J. Hsieh p53 regulates Stat3 phosphorylation and DNA binding activity in human prostate cancer cells expressing constitutively active Stat3 Oncogene 21 2002 3082 3088
15. J. Lin, X. Jin, K. Rothman, H. Lin, H. Tang and W. Burke Modulation of signal transducer and activator of transcription 3 activities by p53 tumor suppressor in breast cancer cells Cancer Res. 62 2002 376 380
16. R. Rayanade, K. Patel, M. Ndubuisi, S. Sharma, S. Omura, J.D. Etlinger, R. Pine and P.B. Sehgal Proteasome- and p53-dependent masking of signal transducer and activator of transcription (Stat) factors J. Biol. Chem. 272 1997 4659 4662
17. R. Rayanade, M. Ndubuisi, J. Etlinger and P. Sehgal Regulation of IL-6 signaling by p53: Stat3- and Stat5-masking in p53-Val135-containing human hepatoma Hep3B cell lines J. Immunol. 161 1998 325 334
18. J. Lin, J. Chen, B. Elenbaas and A.J. Levine Several hydrophobic amino acids in the p53 N-terminal domain are required for transcriptional activation, binding to mdm-2 and the adenovirus 5 E1B 55kd protein Genes Dev. 8 1994 1235 1246
19. X. Jin, W. Burke, K. Rothman and J. Lin Resistance to p53-mediated growth suppression in human ovarian cancer cells retained endogenous wild-type p53 Anticancer Res. 22 2002 659 664
20. V. Lacronique, A. Boureux, V. Valle, H. Poirel, C. Quang, M. Mauchauffe, C. Berthou, M. Lessard, R. Berger, J. Ghysdael and O.A. Bernard A TEL-JAK2 fusion protein with constitutive kinase activity in human leukemia Science 278 1997 1309 1312
21. D. Dittmer, S. Pati, G. Zambetti, S. Chu, A. Teresky, M. Moore, C. Finlay and A.J. Levine Gain of function mutations in p53 Nat. Genet. 4 1993 42 46
22. A. Gualberto, K. Aldape, K. Kozakiewicz and T. Tlsty An oncogenic form of p53 confers a dominant, gain-of-function phenotype that disrupts spindle checkpoint control Proc. Natl. Acad. Sci. USA 95 1998 5166 5171
23. M. Myers, J. Andersen, A. Cheng, M. Tremblay, C. Horvath, J. Parisien, A. Salmeen, D. Barford and N.K. Torks TYK2 and JAK2 are substrates of protein-tyrosine phosphatase 1B J. Biol. Chem. 276 2001 47771 47774
24. W. Kaszubska, H. Falls, V. Schaefer, D. Haasch, L. Frost, P. Hessler, P.E. Kroeger, D.W. White, M.R. Jirousek and J.M. Trevillyan Protein tyrosine phosphatase 1B negatively regulates leptin signaling in a hypothalamic cell line Mol. Cell. Endocrinol. 195 2002 109 118
25. S. Kamizono, T. Hanada, H. Yasukawa, S. Minoguchi, R. Kato, M. Minoguchi, K. Hattori, S. Hatakeyama, M. Yada, S. Morita, T. Kitamura, H. Kato, Ki Nakayama and A. Yoshimura The SOCS box of SOCS-1 accelerates ubiquitin-dependent proteolysis of TEL-JAK2 J. Biol. Chem. 276 2001 12530 12538
26. T. Iwamoto, T. Senga, Y. Naito, S. Matsuda, Y. Miyake, A. Yoshimura and M. Hamaguchi The JAK-inhibitor, JAB/SOCS-1 selectively inhibits cytokine-induced, but not v-Src induced JAK-Stat activation Oncogene 19 2000 4795 4801
27. M.W. Burke, X. Jin, H. Lin, M. Huang, R. Liu, K. Reynolds and J. Lin Inhibition of constitutively active Stat3 in ovarian and breast cancer cells Oncogene 20 2001 7925 7934
28. K. Ishihara, I. Satoh, S. Mue and K. Ohuchi Possible participation of a JAK2 signaling pathway in recombinant rat interleukin-5-included prolongation of rat eosinophil survival Biochim. Biophys. Acta 1536 2001 73 84
29. J. De Vos, M. Jourdan, K. Tarte, C. Jasmin and B. Klein JAK2 tyrosine kinase inhibitor tyrphostin AG490 downregulates the mitogen-activated protein kinase (MAPK) and signal transducer and activator of transcription (Stat) pathways and induces apoptosis myelome cells Br. J. Haematol. 109 2000 823 828
30. S. Miike, A. Nakao, M. Hiraguri, K. Kurasawa, Y. Saito and I. Iwamoto Involvement of JAK2, but not PI 3-kiinase/Akt and MAP kinase pathways, in anti-apoptotic signals if GM-CSF in human eosinophils J. Leukoc. Biol. 65 1999 700 706
31. H.U. Simon, S. Yousefi, B. Dibbert, F. Levi-schaffer and K. Blaser Anti-apoptotic signal of granulocyte-macrophage colony-stimulating factor are transduced via Jak2 tyrosine kinase in eosinophhils Eur. J. Immunol. 27 1997 3536 3539
32. I. Sakai and A.S. Kraft The kinase domain of Jak2 mediates induction of bcl-2 and delays cell death in hematopoietic cells J. Biol. Chem. 272 1997 12350 12358
33. R. Garcia, T.L. Bowman, G. Niu, H. Yu, S. Minton, C.A. Muro-Cacho, C.E. Cox, R. Falcone, R. Fairclough, S. Parsons, A. Laudano, A. Gazit, A. Levitzki, A. Kraker and R. Jove Constitutive activation of Stat3 by the Src and JAK tyrosine kinases participates in growth regulation of human breast carcinoma cells Oncogene 20 2001 2499 2513